Core Viewpoint - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is advancing its Phase 3 clinical trial for MASH, which is crucial for its mission to provide therapeutic solutions for patients [1] Financial Performance - On September 25, 2025, Inventiva reported an earnings per share (EPS) of -$0.64, which was below the estimated EPS of -$0.41, while generating revenue of approximately $5.24 million, slightly surpassing estimates [2][6] - The company has secured a €116 million tranche of structured financing, enhancing its financial position with cash and cash equivalents totaling €146.7 million as of June 30, 2025, ensuring a cash runway until the end of the third quarter of 2026 [3][6] Financial Metrics - Inventiva's financial metrics indicate a challenging environment, with a price-to-earnings (P/E) ratio of approximately -1.46, reflecting negative earnings, and a price-to-sales ratio of about 33.51, indicating that investors are paying $33.51 for every dollar of sales [4][6] - The enterprise value to sales ratio is approximately 28.92, showing the company's valuation relative to its sales [4] - The debt-to-equity ratio is about -0.51, indicating more liabilities than equity, and the current ratio of approximately 0.92 suggests potential difficulty in covering short-term liabilities with short-term assets [5][6]

Core Viewpoint - Altimmune, Inc. has appointed Jerry Durso as Chairman of the Board, succeeding Mitchel Sayare, as the company prepares for Phase 3 development of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Group 1: Leadership Transition - The leadership change is part of the Board's succession planning and aligns with the company's advancement into Phase 3 development of pemvidutide [2] - Jerry Durso has over 30 years of leadership experience in the life sciences industry, with expertise in corporate and commercial strategy [3] - Mitchel Sayare will continue to serve on the Board as an Independent Director after his tenure as Chairman [1][3] Group 2: Pemvidutide Development - Altimmune's lead program, pemvidutide, is a GLP-1/glucagon dual receptor agonist aimed at treating MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [4] - The company expects to hold an End-of-Phase 2 Meeting with the FDA for MASH in the fourth quarter of 2025 [2] Group 3: Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [4]